Literature DB >> 12810600

Crucial role of TrkB ligands in the survival and phenotypic differentiation of developing locus coeruleus noradrenergic neurons.

Pontus C Holm1, Francisco J Rodríguez, Adelheid Kresse, Josep M Canals, Inmaculada Silos-Santiago, Ernest Arenas.   

Abstract

The role of glial cell-line derived neurotrophic factor (GDNF) and neurotrophins in the development of locus coeruleus noradrenergic neurons was evaluated. We found that two neurotrophic factors previously reported to prevent the degeneration of lesioned adult central noradrenergic neurons, GDNF and neurotrophin 3 (NT3), do not play significant roles in the prenatal development of locus coeruleus noradrenergic neurons, as demonstrated by: (1) the lack of alterations in double Gdnf/Nt3 null mutant mice; and (2) the lack of survival-promoting effects of GDNF and/or NT3 in rat E13.5 primary cultures. In contrast, null mutant mice for TrkB, the tyrosine kinase receptor for brain-derived neurotrophic factor and neurotrophin 4, displayed a clear loss of locus coeruleus noradrenergic neurons. In accordance with this, treatment of rat E13.5 primary cultures with TrkB ligands prevented the early loss of noradrenergic neurons and maintained their survival for up to 6 days in vitro. Moreover, an additional 5-10-fold increase in the number of tyrosine hydroxylase positive noradrenergic neurons was detected after 12 hours in culture. This second effect of TrkB ligands involved neither proliferation nor survival, because the number of BrdU- or TUNEL-positive noradrenergic neurons did not change and the effect was elicited by delayed administration of either factor. Because TrkB ligands increased the number of tyrosine hydroxylase-positive cells expressing Phox2a, a paired homeodomain protein required for the development of locus coeruleus noradrenergic neurons, but did not affect the number of Phox2a-positive tyrosine hydroxylase-negative cells, our results suggest that the second effect of TrkB ligands may involve promoting or inducing a noradrenergic phenotype. In summary, our findings suggest that, unlike NT3 and GDNF, TrkB ligands are required and sufficient to promote the development of central noradrenergic neurons.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810600     DOI: 10.1242/dev.00565

Source DB:  PubMed          Journal:  Development        ISSN: 0950-1991            Impact factor:   6.868


  14 in total

Review 1.  Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis.

Authors:  Panos Theofilas; Sara Dunlop; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Neurotrophin receptor heterozygosity causes deficits in catecholaminergic innervation of amygdala and hippocampus in aged mice.

Authors:  O von Bohlen Und Halbach; L Minichiello
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

3.  Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Paul E Polak; Sergey Kalinin; Douglas L Feinstein
Journal:  Brain       Date:  2011-02-04       Impact factor: 13.501

4.  The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease.

Authors:  Sergey Kalinin; Paul E Polak; Shao Xia Lin; Amul J Sakharkar; Subhash C Pandey; Douglas L Feinstein
Journal:  Neurobiol Aging       Date:  2011-06-25       Impact factor: 4.673

5.  BDNF downregulates β-adrenergic receptor-mediated hypotensive mechanisms in the paraventricular nucleus of the hypothalamus.

Authors:  Daniella Thorsdottir; Nicholas C Cruickshank; Zachary Einwag; Grant W Hennig; Benedek Erdos
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-10-11       Impact factor: 4.733

6.  Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease.

Authors:  Beverly M Francis; Jimao Yang; Enid Hajderi; Mary E Brown; Bernadeta Michalski; Joanne McLaurin; Margaret Fahnestock; Howard T J Mount
Journal:  Neuropsychopharmacology       Date:  2012-04-11       Impact factor: 7.853

7.  Development of amyloid burden in African Green monkeys.

Authors:  Sergey Kalinin; Stephanie L Willard; Carol A Shively; Jay R Kaplan; Thomas C Register; Matthew J Jorgensen; Paul E Polak; Israel Rubinstein; Douglas L Feinstein
Journal:  Neurobiol Aging       Date:  2013-04-18       Impact factor: 4.673

8.  Norepinephrine Protects against Amyloid-β Toxicity via TrkB.

Authors:  Xia Liu; Keqiang Ye; David Weinshenker
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 9.  Locus coeruleus: a new look at the blue spot.

Authors:  Gina R Poe; Stephen Foote; Oxana Eschenko; Joshua P Johansen; Sebastien Bouret; Gary Aston-Jones; Carolyn W Harley; Denise Manahan-Vaughan; David Weinshenker; Rita Valentino; Craig Berridge; Daniel J Chandler; Barry Waterhouse; Susan J Sara
Journal:  Nat Rev Neurosci       Date:  2020-09-17       Impact factor: 34.870

10.  Noradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications.

Authors:  David Braun; Jose L M Madrigal; Douglas L Feinstein
Journal:  Curr Neuropharmacol       Date:  2014-07       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.